Open access
Open access
Powered by Google Translator Translator

Global & Public Health (all articles)

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine

12 Apr, 2021 | 01:20h | UTC

Papers Confirm Rare Thrombocytopenia Link to AstraZeneca Vaccine – TCTMD

Study 1: Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination – New England Journal of Medicine

Study 2: Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination – New England Journal of Medicine

 

EMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine

12 Apr, 2021 | 01:18h | UTC

EMA Reviews Link Between Blood Clots and Johnson & Johnson Vaccine – Health Policy Watch

See also: Johnson & Johnson’s COVID-19 vaccine under scrutiny at EMA after 4 ‘serious cases’ of unusual blood clots – Fierce Pharma AND J&J COVID-19 vaccine under EU review over blood clots, AstraZeneca probe grows – Reuters

 

Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil

12 Apr, 2021 | 01:14h | UTC

Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil – Science

Original study: [Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil (study and commentary on Twitter)

 

AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude

9 Apr, 2021 | 03:33h | UTC

AstraZeneca vaccine: Blood clots are “extremely rare” and benefits outweigh risks, regulators conclude – The BMJ

 

A guide to Plan S: the open-access initiative shaking up science publishing

9 Apr, 2021 | 03:11h | UTC

A guide to Plan S: the open-access initiative shaking up science publishing – Nature

Related: Open-access Science Funders Announce Price Transparency Rules for Publishers (several resources on the subject) AND A new mandate highlights costs, benefits of making all scientific articles free to read – Science

 

RCT: New shorter regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease

8 Apr, 2021 | 08:47h | UTC

New regimens of benznidazole monotherapy and in combination with fosravuconazole for treatment of Chagas disease (BENDITA): a phase 2, double-blind, randomised trial – The Lancet Infectious Diseases

Commentary: Chagas disease: Shorter treatment just as effective as longer one, according to study in Bolivia published by The Lancet – Drugs for Neglected Diseases Initiative

 

[Preprint] CoronaVac is 50% effective for reducing symptomatic SARS-CoV-2 infection after the first dose in the setting of high P.1 variant transmission in Brazil

9 Apr, 2021 | 03:36h | UTC

Effectiveness of CoronaVac in the setting of high SARS-CoV-2 P.1 variant transmission in Brazil: A test-negative case-control study – medRxiv

 

Commentary on Twitter (thread – click for more)

 

Editorial by Dr. Antony Fauci: The story behind COVID-19 vaccines

9 Apr, 2021 | 03:32h | UTC

The story behind COVID-19 vaccines – Science

 

Large study finds 1 in 3 Covid-19 survivors have subsequent mental health and neurological conditions

8 Apr, 2021 | 09:14h | UTC

6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records – The Lancet Psychiatry

Commentaries: 1 in 3 Covid-19 patients are diagnosed with a neuropsychiatric condition in the next six months, large study finds – STAT AND A longer look at COVID-19 and neuropsychiatric outcomes – The Lancet Psychiatry AND Largest study to date suggests link between COVID-19 infection and subsequent mental health and neurological conditions – The Lancet AND Covid-19: One in three has neurological or psychiatric condition diagnosed after covid infection, study finds – The BMJ AND One in three survivors of severe Covid diagnosed with mental health condition – The Guardian AND Covid-19 linked to depression and dementia, study suggests – BBC AND Expert reaction to observational study looking at neurological and psychiatric outcomes 6 months after COVID-19 – Science Media Centre AND 1 in 3 COVID Survivors Struggle With Mental Health Issues Months Later – HealthDay

 

Commentary on Twitter (thread – click for more)

 

Audio Interview: Antibody Responses to Natural Infection and Vaccination

9 Apr, 2021 | 03:30h | UTC

Audio Interview: Antibody Responses to Natural Infection and Vaccination – New England Journal of Medicine

 

Cohort study: One in ten have long-term effects 8 months following mild COVID-19

8 Apr, 2021 | 09:12h | UTC

One in ten have long-term effects 8 months following mild COVID-19 – Karolinska Institutet

Original study: Symptoms and Functional Impairment Assessed 8 Months After Mild COVID-19 Among Health Care Workers – JAMA

 

Commentary on Twitter

 

COVAX reaches over 100 economies, 42 days after first international delivery

9 Apr, 2021 | 03:27h | UTC

COVAX reaches over 100 economies, 42 days after first international delivery – World Health Organization

 

Study: Outdoor transmission accounts for 0.1% of Covid-19 cases

8 Apr, 2021 | 09:11h | UTC

Outdoor transmission accounts for 0.1% of State’s Covid-19 cases – The Irish Times

Related: Systematic review: Outdoor transmission of SARS-CoV-2 and other respiratory viruses. “The odds of indoor transmission was very high compared to outdoors (18.7 times)”

 

Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation

9 Apr, 2021 | 03:09h | UTC

Cancer Screening in the Coronavirus Pandemic Era: Adjusting to a New Situation – JCO Global Oncology

 

UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca

8 Apr, 2021 | 09:05h | UTC

UK regulator confirms that people should continue to receive the COVID-19 vaccine AstraZeneca – GOV.UK

Original report: MHRA issues new advice, concluding a possible link between COVID-19 Vaccine AstraZeneca and extremely rare, unlikely to occur blood clots – Medicines and Healthcare products Regulatory Agency

Commentary: Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

Commentary on Twitter

 

WHO Interim statement: A causal relationship between the AstraZeneca COVID-19 vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed

8 Apr, 2021 | 09:09h | UTC

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine – World Health Organization

 

Commentary on Twitter (thread – click for more)

 

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. The benefits of the vaccine continue to outweigh the risks for people who receive it.

8 Apr, 2021 | 09:07h | UTC

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets – European Medicines Agency

Commentaries: In rare instances, AstraZeneca’s Covid-19 vaccine linked to blood clots, regulators say – STAT AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

JCVI statement on use of the AstraZeneca COVID-19 vaccine: “JCVI currently advises that it is preferable for adults aged <30 years to be offered an alternative COVID-19 vaccine, if available.”

8 Apr, 2021 | 09:02h | UTC

JCVI statement on use of the AstraZeneca COVID-19 vaccine: 7 April 2021 – GOV.UK

Commentaries: Covid: Under-30s offered alternative to Oxford-AstraZeneca jab – BBC AND Expert reaction to statements from MHRA and EMA in relation to the AstraZeneca vaccine and rare blood clots and low blood platelets – Science Media Centre

 

Video: Coronavirus Variants and Vaccines

8 Apr, 2021 | 09:00h | UTC

Coronavirus Variants and Vaccines – JAMA

 

CDC Updated Guidance: “It is possible for people to be infected through contact with contaminated surfaces or objects, but the risk is generally considered to be low”

7 Apr, 2021 | 02:00h | UTC

Science Brief: SARS-CoV-2 and Surface (Fomite) Transmission for Indoor Community Environments – Centers for Disease Control and Prevention

Related: Catching COVID from surfaces is very unlikely. So perhaps we can ease up on the disinfecting – The Conversation AND Coronavirus is in the air — there’s too much focus on surfaces – Nature AND COVID-19 rarely spreads through surfaces. So why are we still deep cleaning? – Nature

 

Differences in susceptibility of circulating SARS-CoV-2 variants B.1.1.7 and B.1.351 to neutralization by convalescent plasma or vaccinee (Sinopharm or Sinovac) serum

7 Apr, 2021 | 01:57h | UTC

Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization – New England Journal of Medicine

Related studies: Another study indicates SARS-CoV-2 variant B.1.351, but not variant B.1.1.7, has partial resistance to neutralizing antibodies generated by natural infection or mRNA vaccination – Nature Medicine AND Pfizer coronavirus vaccine found to be moderately less effective against B.1.351 variant AND SARS-CoV-2 variants B.1.351 and P.1 can escape from therapeutic antibodies and evade antibodies induced by infection or mRNA vaccination AND B.1.351 strain of SARS-CoV-2 neutralization titer reduced 8- to 9-fold for Pfizer and AstraZeneca vaccinees. Convalescent plasma and therapeutic antibodies were less effective against this variant as well. AND RCT: Oxford/AstraZeneca vaccine does not protect against mild-to-moderate Covid-19 due to the B.1.351 variant AND New study of Coronavirus variants predicts virus evolving to escape current vaccines, treatments AND Moderna COVID-19 vaccine may be less effective against variant found in South Africa

 

Commentary on Twitter

https://twitter.com/hildabast/status/1379597338956603400

 

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

7 Apr, 2021 | 01:52h | UTC

Editorial: Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When – JAMA Pediatrics

Original study: Trends in Geographic and Temporal Distribution of US Children With Multisystem Inflammatory Syndrome During the COVID-19 Pandemic – JAMA Pediatrics

Commentaries: New findings in COVID-related kids’ syndrome, Kawasaki disease – CIDRAP AND Most kids with serious inflammatory illness had mild COVID – Associated Press

 

Opinion | New COVID variants have changed the game, and vaccines will not be enough. We need global ‘maximum suppression’

7 Apr, 2021 | 01:44h | UTC

New COVID variants have changed the game, and vaccines will not be enough. We need global ‘maximum suppression’ – The Conversation

 

Commentary on Twitter

 

Antibody persistence for at least 6 months after the second dose of mRNA vaccine (Moderna) for Covid-19

7 Apr, 2021 | 01:54h | UTC

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19 – New England Journal of Medicine

Commentary: Moderna COVID Vaccine Offers Protection for at Least 6 Months: Study – HealthDay

Related: [Press release – not published yet] Pfizer/BioNTech vaccine is 91% effective for at least 6 months

 

Commentary on Twitter

 

What’s the new coronavirus variant in India and how should it change their COVID response?

7 Apr, 2021 | 01:42h | UTC

What’s the new coronavirus variant in India and how should it change their COVID response? – The Conversation

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.